Literature DB >> 7185908

Reduction and methylation of sodium arsenate in the rat.

I R Rowland, M J Davies.   

Abstract

After a single oral dose of sodium [74As] arsenate to male Wistar rats, arsenic was rapidly absorbed and accumulated in the blood and to a lesser extent in the liver, kidneys, lungs and spleen. Within 1 h of dosing, arsenic was present in the blood, liver and spleen predominantly in the methylated forms (methylarsonic acid and dimethylarsinic acid), whereas in the lung and kidneys, approximately 50% was in the inorganic form. Intravenous injection of sodium [74As] arsenate resulted in a pattern of arsenic species in the blood and kidneys similar to that seen after oral administration, suggesting that the gut flora does not contribute significantly to biotransformation of arsenic in vivo. Analysis of the forms of arsenic in portal blood after administration of arsenate via the small intestine revealed a rapid reduction of arsenate to arsenite, followed by linear rates of production of methylarsonic acid and dimethylarsinic acid.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7185908     DOI: 10.1002/jat.2550020606

Source DB:  PubMed          Journal:  J Appl Toxicol        ISSN: 0260-437X            Impact factor:   3.446


  4 in total

1.  Tissue distribution and retention of 74As-dimethylarsinic acid in mice and rats.

Authors:  M Vahter; E Marafante; L Dencker
Journal:  Arch Environ Contam Toxicol       Date:  1984-05       Impact factor: 2.804

2.  Reduction and binding of arsenate in marmoset monkeys.

Authors:  M Vahter; E Marafante
Journal:  Arch Toxicol       Date:  1985-06       Impact factor: 5.153

3.  Study of inorganic arsenic methylation by rat liver in vitro: relevance for the interpretation of observations in man.

Authors:  J P Buchet; R Lauwerys
Journal:  Arch Toxicol       Date:  1985-06       Impact factor: 5.153

4.  Study on the Absorption of Arsenic Species in Realgar Based on the Form and Valence.

Authors:  Mingyi Sun; Yaolei Li; Ying Wang; Huimin Wu; Jing Liu; Longtai You; HuLinyue Peng; Huating Huang; Hongyu Jin; Xiaoxu Dong; Changhai Qu; Xingbin Yin; Jian Ni
Journal:  Evid Based Complement Alternat Med       Date:  2022-08-23       Impact factor: 2.650

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.